NCT07422363 2026-03-18Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaNational Cancer Institute (NCI)Phase 1 Not yet recruiting30 enrolled